Study details
Enrolling now
Leveraging Biomarkers for Personalized Treatment of Alcohol Use Disorder Comorbid With PTSD
NYU Langone Health
NCT IDNCT03667846ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
150
Study length
about 5.9 years
Ages
18–70
Locations
1 site in NY
About this study
Researchers are testing whether topiramate, a medication, helps people with both alcohol use disorder and post-traumatic stress disorder (PTSD). The trial will also investigate if certain genetic markers can predict how well someone responds to this treatment. It aims to understand how topiramate works in individuals with both conditions and identify factors that influence treatment success.
Based on ClinicalTrials.gov records.
What participants do
- 1.Placebo
- 2.Take Topiramate
PhasePhase 2
DrugTopiramate
Routeoral
Participation effort
Estimated from trial records. Details can vary by site.
Time + visits
Low11%
Logistics
Moderate50%
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Drug classes
topiramate
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health